AI Article Synopsis
- Therapeutic purging of myeloid cells (MYP) is being explored as a treatment for severe inflammatory conditions, including ulcerative colitis and rheumatoid arthritis.
- A pilot study with 12 chronic HIV patients found that 6 underwent MYP, resulting in a significant decrease in CXCR3-expressing cells for 3 of those patients, unlike the control group.
- The treated patients also saw an increase in circulating CD4 T cells, suggesting that MYP may help regulate immune cell movement and could be beneficial in managing inflammation.
Article Abstract
Therapeutic purging of myeloid cells (monocytes and granulocytes) (MYP) has been proposed as a treatment of severe inflammatory conditions like ulcerative colitis and rheumatoid arthritis. Although direct purging of inflammatory cells contributes to its efficacy, the precise mechanism of action is still unclear. We have tested MYP in a pilot study on 12 patients with chronic HIV infection, of whom 6 underwent MYP. Three/6 MYP patients and none of the controls displayed a strong and long-lasting decrease of cells expressing CXCR3, a major chemokine receptor responsible for trafficking of inflammatory cells. In these three patients, the number of circulating CD4 T cells increased during treatment. The data provide a rational for the use of MYP as a therapeutic tool acting via the modulation of immune cell trafficking.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clim.2003.07.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!